Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism

Bedaquiline (BDQ), an ATP synthase inhibitor, is the first drug to be approved for treatment of multidrug-resistant tuberculosis in decades. Though BDQ has shown excellent efficacy in clinical trials, its early bactericidal activity during the first week of chemotherapy is minimal. Here, using micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Koul, Anil, Vranckx, Luc, Dhar, Neeraj, Göhlmann, Hinrich W.H., Özdemir, Emre, Neefs, Jean-Marc, Schulz, Melanie, Lu, Ping, Mørtz, Ejvind, McKinney, John D., Andries, Koen, Bald, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Pub. Group 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948051/
https://www.ncbi.nlm.nih.gov/pubmed/24569628
http://dx.doi.org/10.1038/ncomms4369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948051/
https://www.ncbi.nlm.nih.gov/pubmed/24569628
http://dx.doi.org/10.1038/ncomms4369

Ejemplares similares